Watch More Highlights
Amber Koehler, MPAS, PA-C, of Mayo Clinic discusses an updated analysis of the CD20xCD3 T-cell engaging bispecific antibody, mosunetuzumab, in patients with relapsed/refractory follicular lymphoma and 2 or more prior lines of therapy. After 3 years of follow-up, durable responses continued to be observed with no new cytokine release syndrome events or serious adverse events reported since the previous analysis (Abstract 603).